However, most reports have shown upregulation of DLEU2 in cancers, including endometrial cancer(EC) [12], renal clear cell carcinoma(ccRCC) [13], esophageal cancer (ESCA) [14], pancreatic cancer (PC) [15], glioma [16], gastric cancer(GC) [17], non-small cell lung cancer (NSCLC) [18], thyroid cancer(TC) [19], and prostate cancer (PCa) [20]. Here, DLEU2 is linked to pachyonychia congenita.